Advisors

The experts who hold us accountable.

Independent clinical leaders actively validating the SYNC-PREVENT™ protocols that will guide patient care — challenging our assumptions and holding the service to the standard they would demand for their own patients.

Clinical oversight is not optional.

SYNC-PREVENT™ makes clinical decisions possible — but it never makes them. Our advisors are actively validating every protocol, escalation pathway, and monitoring threshold that will be used in patient care, testing each against current evidence and real-world clinical judgment before it reaches a single patient.

Each advisor brings a different lens: Dr. Fonseca on diabetes and metabolic disease, Dr. Shi on health economics and outcomes measurement. No single perspective dominates, and no blind spot goes unexamined.

Vivian A. Fonseca, MD, FRCP

Professor of Medicine and Chief, Section of Endocrinology, Tulane University Medical Center

Dr. Fonseca holds the Tullis–Tulane Alumni Chair in Diabetes and serves as Assistant Dean for Clinical Research at Tulane, where his work has centered on how diabetes care performs outside the trial setting — in the primary care offices where most of it actually happens.

A past President for Science and Medicine of the American Diabetes Association, he edited Diabetes Care from 2007 to 2011, has published more than 500 peer-reviewed papers, and co-developed the BRAVO diabetes risk engine. The ADA awarded him its Banting Medal for Leadership and Service, and Expertscape ranks him among the leading diabetes experts worldwide.

Actively validating the diabetes, metabolic, and Zero DFU monitoring protocols ahead of patient care.

Lizheng Shi, PhD, MsPharm, MA

Neal A. & Mary Vanselow Endowed Chair in Health Policy and Management, Tulane University

Dr. Shi founded and directs Tulane's Health Systems Analytics Research Center and holds clinical faculty appointments in endocrinology and psychiatry at Tulane's Department of Medicine. His research puts a blunt question to every care model: does it measurably change outcomes, and at what cost?

He has led or co-led more than 40 funded studies for AHRQ, the CDC, NIH, and PCORI, with over 300 peer-reviewed publications. He co-developed the BRAVO diabetes microsimulation model, serves as Associate Editor of Value in Health and Co-Editor-in-Chief of Pharmacoeconomics and Policy, and received the 2025 Hartzema Distinguished Speaker Award.

Actively validating the outcome measurement and health-economic modeling behind every program.

Next step

Close your blind spot.

Thirty minutes. We'll show you what you're missing between visits.

Talk to Our Team

Complimentary · B2B only · No obligation